Tag Archives: EQT Life Sciences Supports Growth of Tubulis Leading to Major Acquisition by Gilead Sciences

EQT Life Sciences Exits Tubulis Investment Following Gilead Acquisition Agreement in Oncology Sector

(IN BRIEF) EQT Life Sciences has exited its investment in Tubulis following Gilead Sciences’ agreement to acquire the German biotechnology company in a deal valued at up to $5 billion including milestones. EQT supported Tubulis’ development into a clinical-stage oncology … Read the full press release